Background
Adenocarcinoma (ADA) and squamous cell carcinoma (SCC) are rare and aggressive subtypes of bladder cancer. For advanced disease, there are limited therapeutic options and no clear standard of care exists. Therefore, novel therapies based on underlying tumor biology are needed. The purpose of this study was to report on survival of patients with ADA and SCC and to identify potential targets and therapeutic options for these subtypes utilizing next generation sequencing (NGS).